Broad integration across inflammatory mechanisms
The review links Nrf2–Keap1 biochemistry with NF-κB, HO-1, cytokines, adhesion molecules, proteases, inflammasomes, and pharmacological modulators in a single narrative.
↳ Sections 2–7
Abstract
Inflammation is a key driver in many pathological conditions such as allergy, cancer, Alzheimer's disease, and many others, and the current state of available drugs prompted researchers to explore new therapeutic targets. In this context, accumulating evidence indicates that the transcription factor Nrf2 plays a pivotal role controlling the expression of antioxidant genes that ultimately exert anti-inflammatory functions. Nrf2 and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH- associated protein 1 (Keap1), play a central role in the maintenance of intracellular redox homeostasis and regulation of inflammation. Interestingly, Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis, which is a potent anti-inflammatory target. Recent studies showed a connection between the Nrf2/antioxidant response element (ARE) system and the expression of inflammatory mediators, NF-κB pathway and macrophage metabolism. This suggests a new strategy for designing chemical agents as modulators of Nrf2 dependent pathways to target the immune response. Therefore, the present review will examine the relationship between Nrf2 signaling and the inflammation as well as possible approaches for the therapeutic modulation of this pathway.
Key Claims
Primary findingSupported
Nrf2 and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (Keap1), play a central role in the maintenance of intracellular redox homeostasis and regulation of inflammation
extensive mechanistic and preclinical literature supports the direction, though heterogeneous models and unreported source selection limit certainty
Abstract
SecondaryTentative
Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis, which is a potent anti-inflammatory target
categorical wording exceeds a synthesis that acknowledges context dependence and unresolved molecular mechanisms
Abstract
SecondarySupported
Nrf2 negatively controls the NF-κB signaling pathway by multiple mechanisms
multiple cited mechanisms support the direction, while Section 3 documents important context-specific exceptions
Section 3
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Contradictory evidence is directly acknowledged
Section 3 presents opposing findings on Nrf2 and NF-κB family expression, while Section 5 foregrounds evidence that Nrf2 can either suppress or support inflammasome activation.
↳ Sections 3 and 5
Visible pathway from mechanism to therapeutics
Section 6 connects molecular mechanisms to approved DMF use and additional clinical-stage fumarate programs, making the translational pathway concrete.
↳ Section 6
Limitations
No reported source-selection methodology
The article provides no databases, date range, inclusion criteria, or explanation of how its extensive literature was identified and selected.
↳ Absence of a Methods or search-strategy section
Contradictions catalogued rather than resolved
Sections 3 and 5 identify central contradictions but stop at describing them, without a framework for determining when Nrf2 enhances or suppresses inflammation.
↳ Sections 3 and 5
Abstract language overstates mechanistic certainty
The Abstract calls the Nrf2–HO-1 relationship “proved,” while Sections 3–5 describe cell-specific effects, unresolved mechanisms, and controversial inflammasome findings.
↳ Abstract; Sections 3, 4.1, and 5
Nabu Commentary
The article’s strongest feature is its breadth, moving from Nrf2–Keap1 signaling to NF-κB cross-talk, inflammatory mediators, inflammasomes, and therapeutic candidates. Sections 3 and 5 improve balance by presenting findings in which Nrf2 can support rather than suppress inflammatory signaling. The score is constrained by the absence of any search or source-selection method and by the largely descriptive treatment of those contradictions. Section 8 identifies important translational limitations, but Section 9 still advances a broad therapeutic-potential conclusion without fully incorporating them.
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.1
Contribution
2.9
The review consolidates Nrf2–Keap1, NF-κB, HO-1, inflammasome, and pharmacological evidence into one broad account. Its contribution remains limited because it identifies but does not resolve the principal contradictions it surveys.
Sections 3, 5, and 9
it is still controversial whether activation of Nrf2 can lead to the prevention or the induction of aggressive inflammation
Methodological Rigour
2.9
The progression from pathway biology to inflammatory mediators and therapeutics is coherent, and contrary findings receive explicit attention. The article nevertheless operates mainly as a study catalog and reports no search strategy, inclusion criteria, databases, or date range.
Sections 2–7; absence of a Methods or search-strategy section
These conflicting results suggest the need to focus on the role of unknown functions of Nrf2 signaling pathway
Reporting
3.6
Section ordering makes the mechanistic argument followable despite dense terminology and long sequences of individual studies. Precision is reduced by the Abstract’s claim that the Nrf2–HO-1 relationship is “proved” while later sections acknowledge unresolved mechanisms and context dependence.
Abstract; Sections 3, 4.1, and 5
Nrf2 is proved to contribute to the regulation of the heme oxygenase-1 (HO-1) axis
Positioning
3.4
The review engages a large literature and directly presents conflicting NF-κB and NLRP3 findings rather than depicting the field as settled. Cancer risk, off-target effects, blood–brain barrier limitations, and clinical-validation needs are acknowledged, but their implications are not deeply integrated into the therapeutic conclusion.
Sections 3, 5, 8, and 9
More detailed studies are necessary to better characterize potential safety issues
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The central argument remains coherent, but the Abstract contains localized overstatement and the body has citation-format inconsistencies. These issues do not reverse the review’s main interpretation.
Research ConductClean
As a narrative review presenting no original human or animal experiments, the article raises no applicable ethics, registration, data, or code conduct concern in the supplied text.
Flags: 0 declared / 5 total
Reference IntegrityClean
268 of 268 checkable references verified
268 references in manuscript citation details diverge from the cited records for 1 reference
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Aug 2026
Sources: Retraction Watch ✓
Impact Potential
Medium3.2
Relevance
3.4
The review addresses inflammation as an active therapeutic problem and identifies pharmaceutical developers, approved DMF use, and clinical-stage fumarate programs. The application pathway is visible but remains general for most proposed Nrf2 modulators.
Abstract; Sections 6 and 9
many pharmaceutical companies are currently targeting Keap1
Readiness
3.0
The surveyed evidence ranges from molecular and animal models to an FDA-approved therapy for multiple sclerosis and additional clinical trials. The review itself contributes synthesis rather than new translational validation.
Section 6
dimethyl fumarate (DMF), is the only drug approved by US Food and Drug Administration
Generalizability
3.0
Evidence spans numerous cell types, tissues, inflammatory mediators, and disease models. Transfer is constrained by the article’s explicit finding that effects vary by stimulus, cell type, tissue, and inflammasome context.
Sections 3–5
this complex interplay can enhance or impair the inflammatory response, depending on the specific context and stimuli
Trajectory
3.3
The review connects to an active drug-development program and identifies concrete next steps involving biomarkers, disease-directed models, Keap1 cysteines, safety, and clinical trials. Progress is limited by unresolved mechanisms and uncertain safety of sustained activation.
Section 8
sustained Nrf2 induction could lead to the development of other diseases such as cancer
AI-generated, human-governed. Something look off? Contact us to request a review.